

press release

Novo Nordisk UK prepared for all Brexit outcomes

Gatwick, April 11 2019 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is committed to ensuring patients' medicine supplies are unaffected whatever the outcome of Brexit.

Novo Nordisk has been preparing for Brexit for three years and has planned for all future contingencies. We have increased our stock levels and now have around two and a half times our normal stock (roughly 18 weeks' worth). The Government had requested that pharmaceutical companies stockpile 6 weeks' additional operational buffer stock in the UK. We took the decision to stockpile more than the requested amount, demonstrating our commitment to patients living with diabetes in the UK. This significant increase builds on Novo Nordisk's already robust plans for all Brexit scenarios.

To further safeguard against potential border delays in the immediate future, we have also secured pre-bookings of airfreight slots between June and September 2019 to bring essential, lifesaving medicines into the UK, if necessary. As an industry, we continue to work closely with the Department of Health and Social Care in discussing additional freight capacity to ensure supply into the UK.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, "Our first commitment is to ensure that patients treated with our medicines remain unaffected regardless of Brexit outcomes. We believe our Brexit preparations are robust and we have taken all necessary steps to ensure continuity of supply to the UK patients we serve. This is evidenced by our more than doubling of stock levels to 18 weeks and securing airfreight slots from June.

"We have been and continue to work closely with trade associations in the UK and the EU to ensure that the interests of our patients are at the forefront of negotiations. We are also working collaboratively with the Department of Health and Social Care to ensure continuity of supply, irrespective of the outcome of the Government's Brexit negotiations."

-END-

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people with obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.co.uk

*Juliet Scott
Abby Purdy*

*+44 (0)7557490116
+44 (0)787 2506 607*

*zjls@novonordisk.com
Abby.Purdy@Syneoshealth.com*

Novo Nordisk Ltd
Corporate Communications

3 City Place Beehive Ring Road
Gatwick West Sussex RH6 0PA

Telephone:
+44 1293 613555

Internet:
www.novonordisk.co.uk